🇺🇸 FDA
Patent

US 12097213

Sequential treatment of cancers using 6-thio-dG, checkpoint inhibitors and radiation therapy

granted A61KA61K2039/505A61K31/4545

Quick answer

US patent 12097213 (Sequential treatment of cancers using 6-thio-dG, checkpoint inhibitors and radiation therapy) held by The Board of Regents of the University of Texas System expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K2039/505, A61K31/4545, A61K31/7076, A61K39/3955